NAVAMEDIC ASA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33 NOK | -1.79% |
|
-3.51% | -10.08% |
| Apr. 30 | Navamedic ASA Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 13 | Ingerø Reiten Investment Divests Navamedic Stake in NOK95 Million Deal | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 292.1 | 555.8 | 601.2 | 585.7 | 585.7 | - |
| Enterprise Value (EV) 1 | 292.1 | 542.1 | 597.9 | 745.4 | 625.7 | 484.5 |
| P/E ratio | - | 850 x | 20.2 x | 195 x | 14.9 x | 9.74 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 1.39 x | 2 x | 1.57 x | 1.24 x | 0.96 x | 0.84 x |
| EV / Revenue | 1.39 x | 1.95 x | 1.56 x | 1.46 x | 1.03 x | 0.7 x |
| EV / EBITDA | - | 29.8 x | 11.6 x | 14.5 x | 8.86 x | 4.96 x |
| EV / FCF | - | -267 x | 38.1 x | -7.28 x | 44.7 x | 16.1 x |
| FCF Yield | - | -0.37% | 2.62% | -13.7% | 2.24% | 6.19% |
| Price to Book | - | - | 2.87 x | 2.54 x | 1.94 x | 1.55 x |
| Nbr of stocks (in thousands) | 15,292 | 16,346 | 17,228 | 17,433 | 17,433 | - |
| Reference price 2 | 19.10 | 34.00 | 34.90 | 33.60 | 33.60 | 33.60 |
| Announcement Date | 4/30/21 | 2/17/22 | 2/16/23 | 2/15/24 | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net sales 1 | 209.9 | 278.4 | 382.1 | 512 | 608.7 | 695.9 |
| EBITDA 1 | - | 18.2 | 51.69 | 51.57 | 70.64 | 97.76 |
| EBIT 1 | - | 11.46 | 44.44 | 39.64 | 59.3 | 86.84 |
| Operating Margin | - | 4.11% | 11.63% | 7.74% | 9.74% | 12.48% |
| Earnings before Tax (EBT) 1 | - | 2.358 | 42.51 | 10.83 | 51.9 | 80.22 |
| Net income 1 | - | 0.618 | 29.43 | 3.814 | 40.8 | 63.02 |
| Net margin | - | 0.22% | 7.7% | 0.74% | 6.7% | 9.06% |
| EPS 2 | - | 0.0400 | 1.730 | 0.1880 | 2.260 | 3.450 |
| Free Cash Flow 1 | - | -2.028 | 15.69 | -102.4 | 14 | 30 |
| FCF margin | - | -0.73% | 4.11% | -20% | 2.3% | 4.31% |
| FCF Conversion (EBITDA) | - | - | 30.36% | - | 19.82% | 30.69% |
| FCF Conversion (Net income) | - | - | 53.31% | - | 34.31% | 47.6% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Announcement Date | 4/30/21 | 2/17/22 | 2/16/23 | 2/15/24 | - | - |
1NOK in Million2NOK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 90.2 | - | 110.4 | 92.81 | 116 | 121.8 | 124 | 141 | 125.3 | 120.9 | 143 |
| EBITDA 1 | 7.6 | -0.4 | 23.71 | 12.67 | 15.72 | 15.82 | 10.5 | 17.4 | 7.912 | 8.459 | 14 |
| EBIT 1 | 5.053 | - | 21.88 | 10.89 | 13.92 | 13.99 | 8.297 | 12.7 | 3.521 | 4.897 | 11 |
| Operating Margin | 5.6% | - | 19.82% | 11.74% | 12% | 11.49% | 6.69% | 9.01% | 2.81% | 4.05% | 7.69% |
| Earnings before Tax (EBT) 1 | 1.979 | - | 9.575 | 5.244 | 27.16 | - | -17.08 | 10.22 | 0.119 | -0.802 | 8 |
| Net income 1 | 3.025 | - | 7.289 | 2.665 | 20.19 | 13.2 | -15.77 | 6.772 | -0.351 | -1.582 | 7 |
| Net margin | 3.35% | - | 6.6% | 2.87% | 17.41% | 10.84% | -12.72% | 4.8% | -0.28% | -1.31% | 4.9% |
| EPS | 0.1900 | - | 0.4300 | - | - | - | -0.9200 | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/17/22 | 5/12/22 | 8/12/22 | 11/1/22 | 2/16/23 | 5/11/23 | 8/11/23 | 11/1/23 | 2/15/24 | 4/30/24 | - |
1NOK in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 109 | 40 | - |
| Net Cash position 1 | - | 13.6 | 3.3 | - | - | 101 |
| Leverage (Debt/EBITDA) | - | - | - | 2.104 x | 0.5663 x | - |
| Free Cash Flow 1 | - | -2.03 | 15.7 | -102 | 14 | 30 |
| ROE (net income / shareholders' equity) | - | 0.44% | 12.7% | 4.38% | 16.4% | 20.5% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | 12.20 | 13.20 | 17.30 | 21.70 |
| Cash Flow per Share | - | - | - | - | - | - |
| Capex 1 | - | 0.73 | 2.25 | 2.2 | 11 | 11 |
| Capex / Sales | - | 0.26% | 0.59% | 0.43% | 1.81% | 1.58% |
| Announcement Date | 4/30/21 | 2/17/22 | 2/16/23 | 2/15/24 | - | - |
1NOK in Million2NOK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
33.6
NOK
Average target price
49
NOK
Spread / Average Target
+45.83%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -10.08% | 53.02M | |
| +29.68% | 681B | |
| +19.40% | 556B | |
| -4.35% | 361B | |
| +17.65% | 325B | |
| +3.77% | 285B | |
| +13.57% | 235B | |
| +4.36% | 199B | |
| -12.39% | 189B | |
| -3.79% | 157B |
- Stock Market
- Equities
- NAVA Stock
- Financials Navamedic ASA
